Rosetta Capital

Rosetta Capital is a UK-based venture capital firm specializing in the life sciences and medical device sectors. The firm focuses on building leading healthcare companies and breakthrough technologies that can deliver benefits to human lives. Rosetta Capital primarily invests through direct secondary transactions, providing flexible liquidity solutions to investors and corporations. Over its 20+ year history, the firm has made over 50 venture investments, demonstrating extensive expertise in executing complex transactions efficiently.

The firm's investment strategy is centered on direct secondary transactions, allowing them to provide flexible liquidity solutions for investors or corporations seeking to divest some or all of their investment assets or to access additional capital and resources to optimize investment outcomes. Rosetta Capital injects fresh capital into companies during follow-on financings, supporting them through pivotal growth stages. The experienced team collaborates strategically with portfolio company boards, management teams, and co-investors, facilitating successful corporate partnerships, IPOs, and trade sales.

Rosetta Capital has an exceptional track record over its 20+ years, with funds raised and deployed across the life sciences and medical device sectors. The firm has achieved numerous IPO and M&A exits, primarily on NASDAQ and European exchanges. Their portfolio companies are located across Europe, North America, and Asia, reflecting the firm's global investment horizon and commitment to transforming healthcare through strategic investments.